Bioactive lipids-based ph sensitive micelles for co-delivery of doxorubicin and ceramide to overcome multidrug resistance in leukemia

Pharmaceutical Research

Volumn 30, Issue 11, 2013, Pages 2902-2916

  Wang, Yongzhong ^a,b   Ding, Yunfei ^c   Liu, Ziming ^d   Liu, Xingrong ^c   Chen, Li ^a   Yan, Weili ^c  

^a AUBURN UNIVERSITY   (United States)

^b ANHUI UNIVERSITY   (China)

^c SOUTHWEST JIAOTONG UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

ceramide; doxorubicin; leukemia; micelle; oxidized phospholipid

Indexed keywords

1 PALMITOYL 2 AZELAOYL SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 2000]; 2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; C6 CERAMIDE; CERAMIDE; DOXORUBICIN; DRUG CARRIER; MACROGOL 2000; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; ENCAPSULATION; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LIGHT SCATTERING; MALE; MICELLE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; STATIC ELECTRICITY; SURVIVAL TIME; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CERAMIDES; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HYDROGEN-ION CONCENTRATION; LEUKEMIA; LIPIDS; MALE; MICE; MICELLES;

EID: 84886095327     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1121-5     Document Type: Article

References (25)

1. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139-50.
2. Angel I, Bar A, Haring R. Bioactive lipids and their receptors. Curr Opin Drug Discov Dev. 2002;5(5):728-40.
3. Ekiz HA, Baran Y. Therapeutic applications of bioactive sphingolipids in hematological malignancies. Int J Cancer. 2010;127(7):1497-506.
4. Fruhwirth GO, Loidl A, Hermetter A. Oxidized phospholipids: from molecular properties to disease. Biochim Biophys Acta. 2007;1772(7):718-36.
5. Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stockl J. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal. 2010;12(8):1009-59.
6. Wang Y, Chen L, Ding Y, Yan W. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro. Int J Pharmaceut. 2012;422(1-2):409-17.
7. Chen R, Feldstein AE, McIntyre TM. Suppression of mitochondrial function by oxidatively truncated phospholipids is reversible, aided by bid, and suppressed by Bcl-XL. J Biol Chem. 2009;284(39):26297-308.
8. Chen R, Yang L, McIntyre TM. Cytotoxic phospholipid oxidation products. Cell death from mitochondrial damage and the intrinsic caspase cascade. J Biol Chem. 2007;282(34):24842-50.
9. Huang WC, Chen CL, Lin YS, Lin CF. Apoptotic sphingolipid ceramide in cancer therapy. J Lipids. 2011;2011:565316.
10. Ekiz HA, Baran Y. Bioactive sphingolipids in response to chemotherapy: a scope on leukemias. Anti Cancer Agents Med Chem. 2011;11(4):385-97.
11. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007;67(10):4843-50.
12. Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, et al. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J. 2008;22(7):2541-51.
13. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 1995;82(3):405-14.
14. Ma P, Dong X, Swadley CL, Gupte A, Leggas M, Ledebur HC, et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol. 2009;5(2):151-61.
15. Radin NS. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? Eur J Biochem. 2001;268(2):193-204.
16. Tagaram HR, Divittore NA, Barth BM, Kaiser JM, Avella D, Kimchi ET, et al. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut. 2011;60(5):695-701.
17. Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, et al. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood. 2010;116(20):4192-201.
18. van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, et al. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J. 2011;25(1):280-9.
19. Devalapally H, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res. 2008;14(10):3193-203.
20. Pande AH, Kar S, Tripathy RK. Oxidatively modified fatty acyl chain determines physicochemical properties of aggregates of oxidized phospholipids. Biochim Biophys Acta. 2010;1798(3):442-52.
21. Alakhov V, Klinski E, Li SM, Pietrzynski G, Venne A, Batrakova E, et al. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf B. 1999;16(1-4):113-34.
22. Taha TA, Mullen TD, Obeid LM. A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta. 2006;1758(12):2027-36.
23. Rizvi F, Heimann T, Herrnreiter A, O'Brien WJ. Mitochondrial dysfunction links ceramide activated HRK expression and cell death. PLoS One. 2011;6(3):e18137.
24. Romsicki Y, Sharom FJ. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry. 1999;38(21):6887-96.
25. Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci. 2007;10(3):319-31.